Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Nexavar
Sorafenib is a small molecule kinase inhibitor indicated for the treatment of certain types of liver, kidney, and thyroid cancer. It works by blocking multiple kinases involved in tumor growth and angiogenesis, effectively inhibiting cell proliferation and tumor vascularization.
Used to treat advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid carcinoma, and other specific cancers.
Severe bleeding events, including fatalities, have been reported; cardiac ischemic events and hypertension; dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some with fatal outcomes, have occurred. Hepatic failure, including fatalities, has been reported. Embryo-fetal toxicity can occur.
Outcome:
Increased bleeding risk
Mechanism:
Sorafenib inhibits CYP2C9, increasing warfarin levels.
Outcome:
Reduced sorafenib absorption
Mechanism:
Altered gastric pH.
Outcome:
No clinically significant interaction
Mechanism:
None known.
Most likely new formulation: Combination therapy with immunotherapy (2025, 70% confidence)
Based on clinical trial data and post-market surveillance, there is a <1% likelihood of sorafenib being withdrawn from the market for safety reasons in the next 5 years.
Kinase Inhibitor, Antineoplastic
Diarylurea